Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Clinical trial NCT03895970 · COMPLETED

Trial details

NCT number: NCT03895970
Sponsor: Peking Union Medical College Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Liver Neoplasm Malignant Primary Cholangiocarcinoma Combinational Immunotherapy Biomarker

Start date: 2019-04-20
Primary completion: 2021-04-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.